CREXONT® (carbidopa and levodopa) extended-release capsules

New FDA warning for all carbidopa/levodopa therapies: Your doctor should evaluate vitamin B6 levels before and during treatment with carbidopa/levodopa therapies, including CREXONT, as seizures associated with vitamin B6 deficiency have been reported.

35,478+ patients in the United States have been prescribed CREXONT¹

For adults with Parkinson’s disease (PD)

From decorating to dinner to dessert

Stay in step with your day with CREXONT:
More “Good On” time* with less frequent dosing compared with  immediate-release carbidopa/levodopa (IR CD/LD)†

^*“Good On” time is defined as “On” time without troublesome dyskinesia.

^†As seen in a clinical study.

Take your next step

LAURA, on CREXONT since 2024

More “Good On” time* with less frequent dosing compared to IR CD/LD†

Designed to gradually release levodopa

CREXONT is designed to gradually release levodopa in the part of the gut where it is best absorbed, although the exact site and duration of absorption is unknown

More “Good On” time*‡

In the main study, people who took CREXONT an average of 3 times a day achieved 30 minutes more “Good On” time per day than those taking IR CD/LD an average of 5 times a day

Personalized dosing

CREXONT dosing starts at 3 times per day for most patients, though dosing may start at 2 or 3 times per day. After 1 to 3 days, your doctor may adjust your dose or frequency. CREXONT may be dosed up to 4 times a day, though some patients may only take it 2 times a day

^*“Good On” time is defined as “On” time without troublesome dyskinesia.

^†As seen in a clinical study.

^‡Change in “Good On” time was measured by comparing values at the end of study to baseline; P=0.019 vs IR CD/LD.

Ongoing Clinical Study

See how switching from RYTARY or IR CD/LD to CREXONT led to more “Good On” time

See real stories from real people

Learn how CREXONT helps people who are living with Parkinson’s disease.

Play

“Sam’s story is unfolding. And every chapter reminds me of how strong, funny, and brilliant she is. Parkinson’s doesn’t define her; it’s just one part of our story.”

-Derek and Sam

“I don’t know what the future holds,” he says honestly. “But I’m working on it now. And I’m lucky to have people beside me.”

-Gasper

“I tell them, ‘I’ve had Parkinson’s for 5 years. Do I look okay to you?’ And they say, ‘Yeah, you do.’ That moment gives me hope.”

-Dr Morgan

Your CREXONT Story Matters

Are you currently taking CREXONT? We’re inviting people living with Parkinson’s, and their care partners, to share their personal experiences. Your story may help others feel supported and better prepared to have meaningful conversations with their healthcare providers.

Every person’s experience is different. Participation is voluntary and subject to eligibility, consent, and review.^§

CREXONT has transformed innovation into duration

For the first time in Parkinson’s disease, an oral therapy was designed to target where levodopa is best absorbed—the proximal small intestine—making CREXONT the oral CD/LD formulation with the longest-lasting LD plasma levels.^§¶

^§Exact site and duration of absorption are unknown.

^¶In a clinical pharmacology study, the duration of levodopa levels was defined by how long the levels of CREXONT, RYTARY, and IR CD/LD were maintained in the blood above half the maximum concentration.

Are you optimizing your “Good On” time* with your current Parkinson’s disease treatment?

IR CD/LD has been the standard of care for treating PD for many years—it’s designed to work quickly but may wear off quickly too.

Gasper,
on CREXONT since 2025

Want to learn more? Sign up for the CREXONT newsletter

Get inspirational stories, helpful tips, and educational resources delivered to your inbox.

Reference

1. Data on file. Amneal Pharmaceuticals LLC.

^§Not all submissions will be accepted and not all those accepted will be used. All decisions will be made at Amneal’s sole discretion.